# Phase 1 Study of BLB-201 Vaccine in Healthy Young and Older Adults

> **NCT05281263** · PHASE1 · COMPLETED · sponsor: **Blue Lake Biotechnology Inc.** · enrollment: 30 (actual)

## Conditions studied

- Respiratory Syncytial Virus Infections

## Interventions

- **BIOLOGICAL:** CPI-RSV-F Vaccine (BLB-201)

## Key facts

- **NCT ID:** NCT05281263
- **Lead sponsor:** Blue Lake Biotechnology Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-20
- **Primary completion:** 2022-12-05
- **Final completion:** 2023-05-03
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2023-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05281263

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05281263, "Phase 1 Study of BLB-201 Vaccine in Healthy Young and Older Adults". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05281263. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*